Fujifilm makes $800m acquisition
Japan-based Fujifilm has revealed its plan to acquire two cell culture media companies for $800 million.
Last week, Fujifilm announced that it would buy firm Irvine Scientific Sales and related biotech unit IS Japan from JXTG.
Culture media contain the nutrients required for the growth and proliferation of cells. According to Fujifilm they are “essential” for cell culturing in the research and development and manufacturing of biopharmaceuticals and regenerative medicine products.
Irvine and IS Japan offer products including culture media for biopharmaceutical production, in vitro fertilisation and cell therapy.
While Irvine supplies culture media mainly in the US and Europe, IS Japan distributes in Asia, to pharmaceutical companies, bio-ventures, and academia.
The Japan-based company, which has traditionally focused on cameras, has been looking to advance its growth in the healthcare area.
Fujifilm has increased its own manufacturing capacity for antibody drugs through Fujifilm Diosynth Biotechnologies.
It also previously acquired reagent manufacturer Wako Pure Chemical Industries and Cellular Dynamics International, a developer and manufacturer of cell technologies and know-how.
Fujifilm will establish a new facility in Boston for the “marketing of products and services that support the research and development, and manufacturing of new drugs”.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
Join us at LSPN North America on April 26, find out more here.
